Scisparc

Scisparc ROE

The Return on Equity (ROE) of Scisparc (SPRC) as of Nov 21, 2026 is -287.31 %. In the previous year, Return on Equity (ROE) was -77.07 % — a change of 272.81% (lower).

ROE

-287.31 %

YoY

272.81%

Last updated:

In 2025, Scisparc's return on equity (ROE) was -287.31 %, a 272.81% increase from the -77.07 % ROE in the previous year.

The Scisparc ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-4,607.03 USD
Jan 1, 2019
-38,300.00 USD
Jan 1, 2020
-245.24 USD
Jan 1, 2021
-71.26 USD
Jan 1, 2022
-40.19 USD
Jan 1, 2023
-67.27 USD
Jan 1, 2024
-77.07 USD
Jan 1, 2025
-287.31 USD
The Scisparc ROE history
YEARROEYoY
-287.31 %+272.81%
-77.07 %+14.56%
-67.27 %+67.37%
-40.19 %-43.60%
-71.26 %-70.94%
-245.24 %-99.36%
-38,300.00 %+731.34%
-4,607.03 %+5,897.10%
-76.82 %-77.89%
-347.53 %+79.94%
-193.14 %-103.83%
5,039.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? SciSparc Ltd develops cannabinoid-based pharmaceuticals including THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain. The company monetizes through drug development programs targeting specific medical conditions, with pharmaceutical companies and research institutions as primary buyers of these development assets. The firm's revenue streams derive from licensing agreements and partnerships with biopharmaceutical entities seeking to advance cannabinoid-based therapies for unmet medical needs. SciSparc focuses on repurposing Dronabinol into multiple therapeutic applications, creating a diversified portfolio of drug candidates. Its products target neurological disorders, sleep disorders, and infectious diseases, appealing to healthcare providers and patients requiring innovative treatments. The company's business model relies on generating revenue through the sale of development-stage drug assets to larger pharmaceutical firms rather than direct patient sales. The firm's pipeline includes four distinct drug candidates, each addressing different medical conditions. THX-110 targets Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 addresses Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 targets infectious diseases; and THX-160 focuses on pain management. These assets are marketed to biopharmaceutical companies as potential additions to their therapeutic portfolios. Scisparc is one of the most popular companies on Eulerpool.

ROE Details

Decoding Scisparc's Return on Equity (ROE)

Scisparc's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Scisparc's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Scisparc's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Scisparc’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Scisparc stock

Return on Equity (ROE) of Scisparc is -287.31 % in 2025.

Return on Equity (ROE) of Scisparc changed from -77.07 % to -287.31 %, representing a 272.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Scisparc since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Scisparc with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Scisparc

All Key Metrics — Scisparc